Specifically, it focuses on PET tracers like radiolabelled Prostate‐Specific Membrane Antigen (PSMA) and their integration into biopsy‐guided diagnosis, supporting personalised management for prostate cancer patients while adapting the best choice to each patient's clinical situation. Here, FOLH1 is linked to prostate cancer.